M. Wang

RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).

M. R. Gilbert, M. Wang, Kenneth Aldape et al. · Journal of Clinical Oncology · 2011 · 119 citations

Medicine, Oncology, Pharmacology +17

Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199

J. A. Sparano, M. Wang, Simona Di Martino et al. · Journal of Clinical Oncology · 2007 · 40 citations

Medicine, Oncology, Pharmacology +17

Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma.

Nathan Fowler, Peter McLaughlin, Fredrick B. Hagemeister et al. · Journal of Clinical Oncology · 2010 · 23 citations

Medicine, Oncology, Pharmacotherapy +17

AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS)

Caicun Zhou, M. Wang, Ying Cheng et al. · Annals of Oncology · 2018 · 21 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Detection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms

Caicun Zhou, M. Wang, Ying Cheng et al. · Annals of Oncology · 2017 · 13 citations

Medicine, Molecular Medicine, Oncology +17